ppt of eicosanoids and paf

34
S.RAMU 13H61S0108 M.PHARMACY DEPT OF PHARMACOLO

Upload: ramusankula

Post on 07-May-2015

441 views

Category:

Health & Medicine


1 download

DESCRIPTION

By ramu sankula

TRANSCRIPT

Page 1: PPT of Eicosanoids and PAF

S.RAMU13H61S0108M.PHARMACYDEPT OF PHARMACOLOGY

Page 2: PPT of Eicosanoids and PAF

Overview

Eicosanoids are a large group of autocoids with potent effects on virtually every tissue in the body

these agents are derived from metabolism of 20-carbon, unsaturated fatty acids (eicosanoic acids).

Page 3: PPT of Eicosanoids and PAF

.

The eicosanoids include:

1. the prostaglandins

2. thromboxanes

3. leukotrienes

4. hydroperoxyeicosatetraenoic acids (HPETEs)

5. hydroxyeicosatetraenoic acids (HETEs).

Page 4: PPT of Eicosanoids and PAF

Biosynthesis

Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:.

Page 5: PPT of Eicosanoids and PAF

Biosynthesis

Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:

1. Phospholipase A2-mediated production from membrane phospholipids; this pathway is inhibited by glucocorticoids.

Page 6: PPT of Eicosanoids and PAF

Biosynthesis

Arachidonic acid, the most common precursor of the eicosanoids, is formed by two pathways:

1. Phospholipase A2-mediated production from membrane phospholipids; this pathway is inhibited by glucocorticoids.

2. Phospholipase C.

Page 7: PPT of Eicosanoids and PAF
Page 8: PPT of Eicosanoids and PAF
Page 9: PPT of Eicosanoids and PAF

Eicosanoids are synthesized by two pathways:

1. The prostaglandin H synthase (COX, cyclooxygenase) pathway

produces: A. thromboxane B. the primary prostaglandins

prostaglandin E, or PGE prostaglandin F, or PGF prostaglandin D, or PGD)

C. prostacyclin (PGI2)

Page 10: PPT of Eicosanoids and PAF

.2. The lipoxygenase pathway produces:

HPETEs HETEs leukotrienes

Page 11: PPT of Eicosanoids and PAF

RECEPTORSPROSTAGLANDINS

PGE - EP1, EP2, EP3, EP4.

PGF - FP

PGD - DP

THROMBOXANE - TP

PROSTACYCLINS

PGI - IP

LEUKOTRIENES - LT1, LT2, LT3, LT4.

Page 12: PPT of Eicosanoids and PAF

Actions:Vascular smooth muscle

○ PGE2 and PGI2 are potent vasodilators in most vascular beds.

○ Thromboxane is a potent vasoconstrictor.

Page 13: PPT of Eicosanoids and PAF

.Inflammation

○PGE2 and PGI2 cause an increase in blood flow and promote, but do not cause, edema.

○HETEs (5-HETE, 12-HETE, 15-HETE) and leukotrienes cause chemotaxis of neutrophils and eosinophils.

Page 14: PPT of Eicosanoids and PAF

. Bronchial smooth muscle PGFs cause smooth muscle

contraction.○PGEs cause smooth muscle

relaxation.

Page 15: PPT of Eicosanoids and PAF

. Bronchial smooth muscle PGFs cause smooth muscle

contraction.○PGEs cause smooth muscle

relaxation.○Leukotrienes and thromboxane

are potent bronchoconstrictors and are the most likely candidates for mediating allergic bronchospasm.

Page 16: PPT of Eicosanoids and PAF

. Uterine smooth muscle. PGE2 and PGF2a

cause contraction of uterine smooth muscle in pregnant women.

Page 17: PPT of Eicosanoids and PAF

. Uterine smooth muscle. PGE2 and PGF2a

cause contraction of uterine smooth muscle in pregnant women.

The nonpregnant uterusnonpregnant uterus has a more variable response to prostaglandins PGF2a causes contraction

PGE2 causes relaxation.

Page 18: PPT of Eicosanoids and PAF

Gastrointestinal tract ○ PGE2 and PGF2a

- increase the rate of longitudinal contraction in the gut and decrease transit time.

○ The leukotrienes - are potent stimulators of gastrointestinal

smooth muscle.

○ PGE2 and PGI2

- inhibit acid and pepsinogen secretion in the stomach.

Page 19: PPT of Eicosanoids and PAF

Blood ○ TXA2

- is a potent inducer of platelet aggregation.○ PGI2 and PGE2

- inhibit platelet aggregation.○ PGEs

- induce erythropoiesis by stimulating the renal release of erythropoietin.

○ 5-HPETE - stimulates release of histamine

○ PGI2 and PGD - inhibit histamine release.

Page 20: PPT of Eicosanoids and PAF

Therapeutic uses Induction of labor at term. Induction of labor is produced by:

infusion of PGF2 (carboprost tromethamine) [Hemabate] or

PGE2 (dinoprostone) [Prostin E].

Page 21: PPT of Eicosanoids and PAF

Therapeutic abortion:

A.Inducing abortion in the second trimester: Infusion of carboprost tromethamine or Administration of vaginal suppositories

containing dinoprostone

B.inducing first-trimester abortion:○ these prostaglandins are combined with

mifepristone (RU486)

Page 22: PPT of Eicosanoids and PAF

[[Maintenance of ductus

arteriosus

is produced by PGE1 [Prostin VR] infusion

PGE1 will maintain patency of the ductus arteriosus, which may be desirable before surgery.

Page 23: PPT of Eicosanoids and PAF

Treatment of peptic ulcer.

Misoprostol [Cytotec] ○ a methylated derivative of PGE1

○ is approved for use in patients taking high doses of nonsteroidal antiinflammatory drugs (NSAIDs) to reduce gastric ulceration.

Page 24: PPT of Eicosanoids and PAF

Treatment of Glaucoma

Latanoprost - 0.3% solution (Xalatan) Trovoprost (Travatan) Tefluprost (Zioptan)

Bimatoprost (Lumigan)

Page 25: PPT of Eicosanoids and PAF

Adverse effects local pain and irritation bronchospasm gastrointestinal disturbances: nausea,

vomiting, cramping, and diarrhea.

Page 26: PPT of Eicosanoids and PAF

MONTEUKAST

ZAFIRLEUKAST

PRANLEUKAST

ZILEUTON

NSAIDS

CORTICOSTEROIDS

Page 27: PPT of Eicosanoids and PAF

MONTEUKAST

ZAFIRLEUKAST

PRANLEUKAST

ZILEUTON

NSAIDS

CORTICOSTEROIDS

Page 28: PPT of Eicosanoids and PAF

PLATELET ACTIVATINGFACTOR

Page 29: PPT of Eicosanoids and PAF

PAF also termed PAF- acether and AGEPC ( acetyl- glyceyl-ether-phosphorylcholine)

Biologically active phospholipid

Page 30: PPT of Eicosanoids and PAF

BIOSYNTHESIS

Synthesized from acyl-PAF by two step process and under goes ACETYLATION DEACETYLATION

Page 31: PPT of Eicosanoids and PAF

Phospholipid Arachidonic acid

acyl Co A Lys-PAF(INACTIVE)

PLA 2

acetyl hydrolase

PAF (ACTIVE) Lys-PAF (INACTIVE)

acetyl transferase

Page 32: PPT of Eicosanoids and PAF

ACTIONS Vasodilatation Increased vascular permeability Chemotaxis Activation of leukocytes Aggregation of platelets Smooth muscle contraction

Page 33: PPT of Eicosanoids and PAF

ANTAGONISTS

Rupatidine Lexipafant CV-3988 SM-12502 WEB-2086

Page 34: PPT of Eicosanoids and PAF